2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest on Osimertinib in EGFR+ Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Sandip Patel
By 2020 ASCO Virtual Direct™ Highlights FEATURING Sandip Patel
161 views
August 24, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
24:44
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on EGFR+ NSCLC: Adjuvant Gefitinib, Adjuvant Osimer…

Feat. S. Kazmi
09:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in Advanced NSCLC: Nivo/Ipi + 2 Cycles of Che…

Feat. S. Kazmi
08:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstr…

Feat. S. Kazmi
08:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on SCLC: Can a Higher TRT-Dose Prolong Survival…

Feat. S. Patel
07:39
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Localized NSCLC: Does the Addition of Pembro…

Feat. S. Patel
06:39
2020 ASCO Virtual Direct™ Highlights

Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest …

Feat. S. Patel